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Abstract
Introduction
Several characteristics associated with increased risk for Parkinson’s disease (PD) have
been identified, including specific genotypes and various non-motor symptoms. Characteriz-
ing non-motor features, such as cognitive abilities, among individuals considered at-risk for
PD is essential to improving prediction of future neurodegeneration.
Methods
Participants belonging to the following cohorts of the Parkinson Progression Markers Initia-
tive (PPMI) study were included: de novo PD with dopamine transporter binding deficit (n =
423), idiopathic REM sleep behavior disorder (RBD, n = 39), hyposmia (n = 26) and non-PD
mutation carrier (NMC; Leucine-rich repeat kinase 2 (LRRK2) G2019S (n = 88) and gluco-
cerebrosidase (GBA) gene (n = 38) mutations)). Inclusion criteria enriched the RBD and
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Results
The RBD cohort performed significantly worse than the hyposmia and NMC cohorts on
Symbol Digit Modality Test (mean (SD) 32.4 (9.16) vs. 41.8 (9.98), p = 0.002 and vs. 45.2
(10.9), p<0.001) and Judgment of Line Orientation (11.3 (2.36) vs.12.9 (1.87), p = 0.004 and
vs. 12.9 (1.87), p<0.001). The RBD cohort also performed worse than the hyposmia cohort
on the Montreal Cognitive Assessment (25.5 (4.13) vs. 27.3 (1.71), p = 0.02). Hyposmics
did not differ from PD or NMC cohorts on any cognitive test score.
Conclusion
Among individuals across a spectrum of risk for PD, cognitive function is worse among
those with the characteristic most strongly associated with future risk of PD or dementia with
Lewy bodies, namely RBD.
Introduction
In Parkinson’s disease (PD), the second most common neurodegenerative disorder, motor
symptoms constitute the core diagnostic criteria[1]. However, the pathophysiological changes
of PD begin years to decades before clear-cut motor symptoms manifest[2]. These manifesta-
tions include a cluster of at-risk characteristics or prodromal manifestations. Therefore, the
definition of PD has been extended to include individuals considered at-risk for PD. These fall
along a broad spectrum of risk: asymptomatic carriers of mutations associated with PD, as well
as individuals with prodromal non-motor clinical signs/symptoms, biomarker findings, or
genetic polymorphisms that alone or in combination predict increased risk for PD to varying
degrees[3].
In many cases among individuals at-risk for PD, the course/progression to the motor mani-
festations of PD aligns well, both anatomically and temporally, with the neuropathological
staging system proposed by Braak[4,5], as follows: (1) In Braak stage I, involvement of the
olfactory tubercle and medulla manifests clinically with hyposmia (i.e., impaired olfaction),
reduced heart rate variability, and other manifestations of autonomic dysfunction; (2) In
Braak stage II, there is involvement of more rostral brainstem structures, including the seroto-
nergic dorsal raphe nuclei, which clinically may manifest with anxiety and depression, and the
glutamatergic peri-locus coeruleus, which has been hypothesized to lead to REM sleep behav-
ior disorder [RBD]. Involvement of norepinephrine-producing neurons in the locus coeruleus
at this stage may also mediate subtle abnormalities in cognition [e.g., attention and working
memory] reported in the prodromal PD state[6].
Data on cognition in individuals at-risk for PD are limited, and cognitive changes in sub-
groups across the at-risk spectrum have not been well described. In addition to enrolling a
cohort of de novo PD patients, the Parkinson Progression Markers Initiative (PPMI) study
also enrolled individuals without a diagnosis of PD but who are considered at-risk for PD
based on the presence of one of the following characteristics: genetic profile (i.e., carriers of
Leucine-rich repeat kinase 2 (LRRK2) G2019S or glucocerebrosidase (GBA) gene mutations),
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hyposmia, or a diagnosis of RBD. This cohort thus represents a mixture of individuals, some
who are at-risk for PD but who will never develop it, as well as individuals that may be in the
PD prodrome, presumed to be manifesting the earliest signs of neurodegeneration. For brev-
ity, in this manuscript this cohort will hereto forth be referred to as the “at-risk PPMI cohort”.
The at-risk PPMI cohort provides a unique opportunity to investigate differences in cognition
among at-risk subgroups. Based on Braak staging, we hypothesized a “gradient of prodromal-
ness” in which the RBD cohort would have worse cognition than the hyposmia cohort, which
in turn would have worse cognition than the non-PD mutation carrier (NMC cohort). In this
study, we investigated this hypothesis in the at-risk PPMI cohort.
Methods
Study participants
PPMI is a multicenter, international, longitudinal cohort study. Study aims, methodology, and
details of study assessments have been published elsewhere[7] and are available on the PPMI
website (http://www.ppmi-info.org/study-design). PPMI includes several study cohorts. Inclu-
sion criteria vary based on the cohort, as detailed below. Exclusion criteria applying to all
cohorts included in this analysis were: (i) dementia based on the site investigator’s clinical
assessment and (ii) any medical conditions precluding participation at the discretion of the
investigator.
PPMI includes 4 cohorts of participants included in this analysis:
1. PD cohort (n = 423): newly diagnosed, untreated at enrollment. PD patients were required,
at baseline, to have been diagnosed within two years of study enrollment, have dopamine
transporter (DAT) binding deficit based on visual interpretation of DaTscan SPECT (as
described in the supporting information), and be untreated for PD.
2. RBD cohort (n = 39). RBD was diagnosed by the site principal investigator (based on clini-
cal history along with polysomnographic findings, where available). Exclusion criteria for
this cohort included motor signs that meet criteria for a diagnosable parkinsonian syn-
drome based on the opinion of the investigator. In order to enrich this cohort with individ-
uals presumed to have incipient motor PD[8], they underwent DAT imaging. All those who
had DAT binding deficit (as defined in S1 File) qualified for inclusion in PPMI. In addition,
approximately 10% of those without a DAT binding deficit were also included, with the
goal of keeping site investigators blinded to DAT SPECT results.
3. Hyposmia cohort (n = 26). Olfaction was measured using the University of Pennsylvania
Smell Identification Test (UPSIT)[9]. Any individual without a diagnosis of PD was eligible
to undergo olfactory testing. Recruitment for this cohort occurred from various sources
including the community (via targeted online ads) and PPMI sites’ outpatient clinics. Indi-
viduals expressing interest in olfactory testing were mailed an UPSIT, and they mailed com-
pleted UPSITs back to a central “olfaction core” which scored the smell tests and contacted
individuals meeting criteria for hyposmia. Hyposmia was defined as a score of<10th per-
centile for age and sex. These individuals were then seen at a PPMI site for a screening visit.
In order to enrich this cohort with individuals presumed to have incipient motor PD[10–
12]) a DAT SPECT was performed at screening. All those who had a DAT binding deficit
qualified for inclusion in PPMI. In addition, approximately 10% of those without a DAT
binding deficit were also included, with the goal of keeping site investigators blinded to
DAT SPECT results.
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4. Non-manifesting mutation carrier (NMC) cohort (n = 126). These were individuals without
a diagnosis of PD who are carriers of the G2019S mutation in the LRRK2 gene (n = 88), or
the following GBA mutations (n = 38): 84GG (c.115+1G>A), IVS2+1G>A, c.1226A>G
(N370S), c.1448T>C (L444P). These individuals were identified through various sources.
For example, any adult who was Ashkenazi Jewish and had a 1st degree relative with PD
could be referred for telephone-based genetic counseling and screened for the LRRK2
G2019S and GBA mutation, or individuals with a known mutation (regardless of how it
was identified) could have self-referred for participation. PPMI also enrolled carriers of
synuclein (SCNA) gene mutations but given the small number enrolled at the time of this
analysis (n = 5) this subgroup was not included.
The study protocol was approved by the institutional review board of the University of
Rochester. Institution review board approval was also obtained at each PPMI site. Written
informed consent was obtained from all study participants.
Assessments
Assessments obtained on the PPMI cohort and considered in these analyses included:
• Demographics and handedness: age at baseline, sex, education, and self-reported handed-
ness (because only 2% of the cohort reported mixed handedness these were combined with
the right-handed group).
• Neuropsychological test battery (the domains tested by the respective test is indicated, pre-
ceding the test name): Global cognitive function—Montreal Cognitive Assessment (MoCA)
[13], Processing speed/attention—Symbol Digit Modalities Test (SDMT)[14], Executive
function/working memory—Semantic fluency[15] (number of words generated for animals,
vegetables, fruit) and Letter-Number Sequencing (LNS), Verbal memory—Hopkins Verbal
Learning Test-Revised (HVLT-R)[16], immediate and delayed free recall and recognition
discrimination, Visuospatial function—Benton Judgment of Line Orientation (JOLO)
15-item (split-half) version[17].
Participants were categorized as having mild cognitive impairment (MCI) if they scored
>1.5 SD below the mean on2 detailed neuropsychological test scores, regardless of cognitive
domain [18].
• Depression assessment—15-item Geriatric Depression Scale (GDS-15) [19]
• DAT SPECT—DAT SPECT was performed as previously described[7]. A binary determina-
tion of DAT binding deficit was made in the at-risk cohort based on the definition described
in supplementary material. The striatal specific binding ratio (SBR) was also considered.
• Olfaction—UPSIT scores were used to categorize all participants into olfactory levels of nor-
mosmia, hyposmia, and anosmia based on age and sex-specific normative values[9,20],
• RBD—REM Sleep Behavior Disorder Questionnaire (RBDSQ)[21]. The cutoff score indica-
tive of possible RBD was6 in the PD cohort[22] and5 in all other cohorts[21].
Statistical analysis
All clinical and biomarker data included in this study were downloaded from the PPMI data-
base on August 1, 2016. Baseline characteristics were summarized using descriptive statistics,
and compared across cohorts using generalized linear models assuming a normal distribution
for continuous variables and a binomial distribution for categorical variables.
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Differences in variables of interest among the 4 cohorts were examined using generalized
linear models for continuous variables and logistic regression models for categorical variables.
The following variables were examined, each in a separate model: cognitive test scores, pres-
ence of MCI, UPSIT, presence of DAT binding reduction, DAT SSBR, and presence of possible
RBD based on RBDSQ score. A normal distribution was assumed for continuous variables and
a binomial distribution for categorical variables. Age, sex, education and GDS-15 score were
included as co-variates. For any variables that showed a significant difference with a p-
value = 0.1 or less, pairwise comparisons between all cohort combinations were performed,
and values with p<0.05 were regarded as statistically significant.
A sub-group analysis, utilizing the same statistical tests, was performed comparing the GBA
and LRRK2 mutation carriers that constitute the NMC cohort.
Adjustments for multiple comparisons were not made given the exploratory nature of this
analysis.
Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
Baseline demographic characteristics are shown in Table 1.
Mean age, sex, education level, and GDS-15 were significantly different between at least
two of the cohorts. As a result, all subsequent between-group analyses were adjusted for age,
sex, education and GDS-15 scores.
Olfaction was significantly more impaired, and RBDSQ score higher, in the PD, RBD, and
hyposmia cohorts compared to the NMC cohort. As expected, most subjects in the PD, RBD,
and hyposmia cohorts had a DAT binding deficit, whereas less than 20% of the NMC cohort
had a DAT binding deficit. The mean striatal SBR was significantly lower in the PD cohort
compared to all other cohorts (p<0.0001 for all pairwise comparisons). Mean striatal SBR was
significantly lower in the RBD cohort compared to the hyposmia (p = 0.0009) and NMC
(p<0.0001) cohorts, and the hyposmia cohort compared to the NMC cohort (p<0.0001).
Mean scores on the neuropsychological test battery in the four cohorts are shown in
Table 2.
P-values for pairwise comparisons between the different cohorts are shown in Fig 1. The
measure of global cognition (MoCA score) was worse in the RBD cohort compared to the PD
and hyposmia cohorts. The RBD cohort performed significantly worse on measures of two
cognitive domains compared to all other cohorts: processing speed/attention (SDMT) and
visuospatial function (JOLO) (Fig 1). Hyposmics did not differ from PD or NMC cohorts in
any cognitive domain. The PD cohort performed significantly worse than the NMC on a mea-
sure of executive function (semantic fluency) and processing speed/attention (SDMT).
The RBD cohort had the highest prevalence of MCI compared to the other cohorts; how-
ever, none of the differences between groups was significant after adjusting for age, sex, educa-
tion, and GDS-15 score.
In comparing the LRRK2 and GBA cohorts, the LRRK2 mutation carriers had lower scores
on both global cognition (MoCA) and a measure of verbal memory (HVLT immediate free
recall) (Table 3).
Discussion
In this study, we demonstrate significant differences in cognition among four cohorts pre-
sumed to be at-risk for PD, but to varying extents. As hypothesized, the RBD cohort performed
worse than the other at-risk cohorts. RBD is thought to reflect a prodromal PD state resulting
from neurodegeneration of pontine nuclei, including the glutamatergic peri-locus coeruleus.
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
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Table 1. Demographics, clinical, and DAT SPECT characteristics in the PD, RBD, Hyposmia, and non-PD mutation carrier groups.
Variable PD cohort
(N = 423)
RBD
cohort
(N = 39)
Hyposmia
cohort
(N = 26)
Non-PD
mutation
carriers
(N = 126)
Asymptomatic
LRRK2 mutation
carriers
(N = 88)
Asymptomatic GBA
mutation carriers
(N = 38)
p-value for test
of difference
between groups)
p-value for test of
difference between
LRRK2 and GBA
groups only
Age Mean (SD;
range)
61.6 (9.7;
33–85)
69.6 (5.5;
59–82)
68.1 (6.2;
61–83)
62.2 (7.3; 50–
84)
61.6 (7.1; 50–81) 63.6 (7.5; 52–84) < 0.0001 0.1578
Sex Male N (%):
Female N (%)
277 (65):
146 (35)
33 (85): 6
(15)
18 (69): 8
(31)
83 (66):43
(34)
32 (36):56 (64) 11 (29):27(71) < 0.0001 0.4214
Education
< 13 yrs N(%):
13 years N (%)
76 (18):347
(82)
14 (36):25
(64)
3 (12): 23
(88)
26 (21):97
(77)
23 (26):63 (72) 3 (8):34 (89) 0.0433 0.0341
Number with
Missing Data N
(%)
0 0 0 3 (2) 2 (2) 1 (3)
Self-reported
handedness
Right or Mixed N
(%):Left N(%)
385 (91):38
(9)
39 (100):0
(0)
23 (88)3
(12)
104 (83): 18
(14)
73 (83): 12 (14) 31 (82): 6 (16) 0.1261 0.8729
Number with
Missing Data N
(%)
0 0 0 4 (3) 3 (3) 1 (3)
Geriatric
Depression Scale-
15
Mean (SD; range) 2.3 (2.4;
0–14)
2.8
(2.6;0–10)
1.5 (1.5;
0–6)
1.7 (2.1; 0–9) 1.6 (2.0) 1.9 (2.4; 0–9) 0.0063 0.4126
Number with
Missing Data N
(%)
0 0 0 6 (5) 5 (6) 1 (3)
UPSIT
(categorical)
Normosmia N (%) 39 (9) 1 (3) 0 (0) 44 (35) 27 (31) 17 (45)
Hyposmia N (%) 237 (56) 18 (46) 7 (27) 80 (63) 57 (65) 18 (47) < 0.0001 0.1722
Anosmia N (%) 147 (35) 18 (46) 19 (73) 3 (2) 2 (2) 1 (3)
Number with
Missing Data N
(%)
0 (0) 2 (5) 0 (0) 4 (3) 2 (2) 2 (5)
REM sleep
behavior disorder
(score 5)
No N (%): Yes N
(%)
312 (74):
108 (26)
4 (10): 34
(87)
15 (58): 11
(42)
92 (73): 23
(18)
67 (76):16 (18) 25 (66):7 (18) < 0.0001 0.7104
Number with
Missing Data N
(%)
3 (1) 1 (3) 0 11 (9) 5 (6) 6 (16)
DAT binding
deficit
No N (%):Yes N
(%)
1 (0.2): 413
(98)
3 (8): 36
(92)
4 (15): 22
(85)
83 (66): 18
(14)
56 (64):16 (18) 27 (71):2 (5) < 0.0001 0.0332
Number with
Missing Data N
(%)
4 (1) 0 0 25 (20) 16 (18) 9 (24)
Mean striatal
specific binding
ratio
(Continued)
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Involvement of nearby nuclei, including the noradrenergic locus coeruleus as well as the cho-
linergic pedunculopontine nucleus, could account for some of the cognitive dysfunction seen
in RBD cases. Furthermore, the lower mean striatal SBR seen in this cohort compared to the
hyposmia and NMC cohort indicates greater nigrostriatal dysfunction which could also help
account for the worse cognition in this cohort[23].
Interestingly, and not consistent with our hypothesis, the RBD cohort was also more cogni-
tively impaired than the PD cohort. The RBD cohort was predominantly older, male, and had
a lower education level than other cohorts, all risk factors for cognitive impairment. It is likely
that approximately half of the RBD cohort will develop dementia with Lewy Bodies [DLB][24]
rather than idiopathic PD, in which cognitive dysfunction is mild early on[25]. This may partly
explain the worse cognition in this cohort, possibly mediated by concomitant neurodegenera-
tive disease pathology in the cortex and cholinergic nucleus basalis of Meynert, specifically
Lewy body disease with or without Alzheimer’s disease pathology. The RBD cohort performed
worse compared to all other cohorts in measures of processing speed/attention (SDMT) and
visuospatial function (JOLO). This is of note considering that among individuals with RBD,
abnormalities in tests of attention (as well as executive function) are predictive of future risk of
DLB in RBD[26], and visuospatial dysfunction is a hallmark of DLB[27].
The hyposmia cohort did not differ from the PD cohort or the NMC cohort in any of the
cognitive measures, despite significantly lower striatal SBRs. This is in contrast to the Parkin-
son Associated Risk Syndrome (PARS) cohort, in which individuals with both hyposmia and
DAT binding reduction performed significantly worse on measures of global cognition, execu-
tive function/working memory, and verbal memory[6] compared to normosmics or hypos-
mics without DAT binding reduction. This discrepancy may be due to the small sample size
(and reduced power) of the hyposmia cohort or to true intrinsic differences between the PPMI
and PARS cohorts.
The NMC cohort includes predominantly healthy individuals, and the low prevalence of
DAT binding reduction in that cohort suggests that at baseline they are indeed “low” on the
spectrum of “prodromalness” (i.e., most of them have a low risk of conversion to motor PD).
However, they are genetically heterogeneous and their risk of PD and its manifestations is
likely largely influenced by their genotype. GBA mutations confer increased risk of cognitive
Table 1. (Continued)
Variable PD cohort
(N = 423)
RBD
cohort
(N = 39)
Hyposmia
cohort
(N = 26)
Non-PD
mutation
carriers
(N = 126)
Asymptomatic
LRRK2 mutation
carriers
(N = 88)
Asymptomatic GBA
mutation carriers
(N = 38)
p-value for test
of difference
between groups)
p-value for test of
difference between
LRRK2 and GBA
groups only
Mean (SD) 1.4
(0.40;0–3)
1.5 (0.39;
1–3)
1.9 (0.40;
1–3)
2.6 (0.50;
1–4)
2.5 (0.49’ 2–4) 2.7 (0.50; 1–4) < 0.0001 0.0002
Number with
Missing Data N
(%)
4 (1) 0 0 25 (20) 16 (18) 9 (24)
Generalized linear models were used to test for differences in continuous variables and a logistic regression model was used to test for differences in categorical
variables
 The cutoff score indicative of possible RBD was6 in the PD cohort[21] and5 in all other cohorts[20]. Note that the diagnosis of RBD in the RBD group was based
on interview and not necessarily RBDSQ score. Furthermore, it is likely the majority of individuals with RBD in the RBD group were being treated at the time of
enrollment in PPMI/completion of this questionnaire.
1 subject was enrolled but terminated study participation prior to undergoing DaTscan. 3 subjects were enrolled at sites in a country in which DaTscan is not
available. These participants underwent AV-133 imaging to determine their eligibility for study participation
https://doi.org/10.1371/journal.pone.0201964.t001
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Table 2. Cognitive performance in the PD, RBD, hyposmic, and NPD-GC arms.
Cognitive Domain Measure PD Cohort
(N = 423)
RBD Cohort
(N = 39)
Hyposmic
Cohort
(N = 26)
Non-PD Mutation
Carriers
(N = 126)
p-value for test of difference
between groups)
Mild cognitive
impairment
2 or more tests > 1.5 SD
below mean
yes N(%): no N(%) 46 (10.9): 373
(88.2)
11 (28.2): 27
(69.2)
1 (3.8): 24
(92.3)
12 (9.5): 85 (67.5) 0.1477
Number with Missing Data 4 (0.9%) 1 (2.6%) 1 (3.8%) 29 (23.0)
Global cognition MoCA
Mean (SD; range) 27.1 (2.32; 17–
30)
25.5 (4.13;
11–30)
27.3 (1.71; 23–
30)
26.9 (2.54; 19–30) 0.0451
Number with Missing Data 3 (1) 0 0 3 (2)
Verbal memory HVLT Immediate Recall
Mean (SD) 24.4 (4.98;
9–36)
21.1 (5.12;
9–33)
22.8 (5.55; 12–
33)
25.5 (5.89; 5–35) 0.3562
Number with Missing Data
N (%)
1 (0.2) 1 (3) 1 (4) 4 (3)
HVLT Delayed Recall
Mean (SD; range) 8.4 (2.52; 0–12) 6.5 (3.24;
0–12)
7.6 (3.37; 0–12) 9.1 (2.80; 0–12) 0.1496
Number with Missing Data
N (%)
1 (0.2) 1 (3) 1 (4) 4 (3)
HVLT Delayed
Recognition
Mean (SD; range) 11.2 (1.23;
0–12)
10.5 (1.37;
7–12)
11.1 (1.39;
6–12)
11.2 (1.68; 0–12) 0.6388
Number with Missing Data
N (%)
2 (0.5) 1 (3) 1 (4) 7 (5)
Visuospatial function Benton Judgment of Line
Orientation
Mean (SD; range) 12.8 (2.13;
5–15)
11.3 (2.36;
3–15)
12.9 (1.87;
8–15)
12.8 (2.05; 5–15) 0.001
Number with Missing Data
N (%)
1 (0.2) 2 (5) 1 (4) 4 (3)
Processing speed/
attention
Symbol Digit Modalities
Test
Mean (SD; range) 41.2 (9.73;
7–82)
32.4 (9.16;
15–56)
41.8 (9.98; 16–
55)
45.0 (10.9; 0–74) < 0.0001
Number with Missing Data
N (%)
1 (0.2) 2 (5) 1 (4) 7 (5)
Executive function/
working memory
Letter-Number
Sequencing
Mean (SD; range) 10.6 (2.66;
2–20)
9.0 (3.33;
3–17)
10.2 (1.80;
6–14)
10.7 (2.99; 2–20) 0.3796
Number with Missing Data
N (%)
1 (0.2) 1 (3) 1 (4) 4 (3)
Semantic Fluency total
Mean (SD; range) 48.7 (11.6; 20–
103)
43.7 (8.74;
27–65)
47.0 (13.4; 26–
75)
54.1 (13.8; 18–98) 0.0084
Number with Missing Data
N (%)
1 (0.2) 1 (3) 1 (4) 4 (3)
Analyses are adjusted for age, sex, education and GDS-15 score
https://doi.org/10.1371/journal.pone.0201964.t002
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dysfunction among individuals with PD[28], and this may result, pathophysiologically, from a
synergistic effect between glucocerebrosidase dysfunction and alpha-synuclein pathology[29].
There are limited data on cognition in asymptomatic GBA mutation carriers. Similarly, there
are limited data on cognition in asymptomatic LRRK2 G2019S carriers, but what data are
available suggest that at least a subset of such individuals have worse performance on measures
of executive function compared to non-carriers[30]. A study comparing cognitive function
among asymptomatic GBA and LRRK2 mutation carriers found no differences between the
cohorts[31]. In our cohort, while cognition was overall similar between the two cohorts, there
were some differences. LRRK2 cohort participants had a lower mean MoCA and performed
worse on a measure of verbal memory. Some of these findings may again be explained by evi-
dence of greater nigrostriatal dysfunction[23] in the LRRK2 cohort. In addition, LRRK2 has
higher penetrance for PD compared to GBA mutations [by age 85, estimates are approximately
30% for LRRK2[32] vs. 10% GBA mutations[33,34]]. Therefore, all other things being equal, a
greater proportion of individuals at-risk for PD on the basis of LRRK2 mutations would be
expected to have some degree of neuronal dysfunction or neurodegeneration [that could
potentially manifest with cognitive dysfunction] compared to at-risk GBA mutation carriers.
Fig 1. Graphical comparison of select neuropsychological test battery scores in the 3 at-risk groups. The scores for MoCA, semantic fluency, Symbol Digit
Modalities Test (SDMT), and Benton Judgment of Line Orientation are shown for the 3 at-risk groups. Asterisks indicate significant difference in pairwise comparisons
between groups.
https://doi.org/10.1371/journal.pone.0201964.g001
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In PD, GBA mutations associated with more severe phenotypes, such as L444P, are much
more strongly associated with risk of dementia compared to other GBA mutations[35]. The
sample size of the asymptomatic GBA cohort in PPMI limits genotype-phenotype correlations
within this cohort at this time but will be of great interest as the sample size of this cohort
increases (recruitment to this cohort is ongoing).
There are several limitations of this study, The Movement Disorders Society (MDS)
research criteria for prodromal PD[3] were proposed after the at-risk cohort of PPMI was
recruited and thus these criteria were not accounted for in the inclusion criteria. Rather, the
at-risk PPMI cohorts were selected based on a range of at-risk or prodromal characteristics
Table 3. Cognitive performance in the LRRK2 G2019S and GBA mutation carrier groups.
Cognitive Domain Measure Asymptomatic LRRK2
mutation carriers
(N = 88)
Asymptomatic GBA
mutation carriers
(N = 38)
p-value for test of difference between
LRRK2 and GBA groups only
Global cognition MoCA
Mean (SD; range) 26.5 (2.72; 19–30) 27.6 (1.86; 20–30) 0.0427
Number with Missing Data
N (%)
2 (2) 1 (3)
Verbal memory HVLT Immediate Recall
Mean (SD; range) 24.6 (6.03; 5–34) 27.5 (5.05; 14–35) 0.0181
Number with Missing Data
N (%)
2 (2) 2 (5)
HVLT Delayed Recall
Mean (SD; range) 8.8 (2.96; 0–12) 9.7 (2.27; 4–12) 0.1216
Number with Missing Data
N (%)
2 (2) 2 (5)
HVLT Delayed
Recognition
Mean (SD; range) 11.1 (1.89; 0–12) 11.5 (0.93; 8–12) 0.3895
Number with Missing Data
N (%)
3 (3) 4 (11)
Visuospatial function Benton Judgment of Line
Orientation
Mean (SD; range) 12.7 (2.08; 5–15) 12.9 (1.90; 8–15) 0.2660
Number with Missing Data
N (%)
2 (2) 2 (5)
Processing speed/
attention
Symbol Digit Modalities
Test
Mean (SD; range) 44.2 (11.7; 0–74) 47.0 (8.49; 29–68) 0.3235
Number with Missing Data
N (%)
3 (3) 4 (11)
Executive function/
working memory
Letter-Number
Sequencing
Mean (SD; range) 10.7 (3.14; 2–20) 10.9 (2.63; 6–18) 0.7698
Number with Missing Data
N (%)
2 (2) 2 (5)
Semantic Fluency total
Mean (SD; range) 54.0 (14.6; 18–98) 54.1 (11.5; 25–78) 0.7457
Number with Missing Data
N (%)
2 (2) 2 (5)
Analyses are adjusted for age, sex, education and GDS-15 score
https://doi.org/10.1371/journal.pone.0201964.t003
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narrower than what the MDS criteria encompass, and the RBD cohort was also enriched for
individuals with DAT binding deficit. These inclusion criteria likely limit the generalizability
of our findings to other at-risk cohorts and the general population of individuals at-risk for
PD. The latter, combined with the relatively small numbers in some of the cohorts, as well as
missing data, limit conclusions that can be drawn, especially with respect to the hyposmia
cohort. In addition, participants in all cohorts of the PPMI study may not be representative of
the respective populations from which they are drawn. Comparison to individuals without
known risk of PD was not possible as the healthy control cohort of PPMI was recruited with
different exclusion criteria specifically in regards to cognition (i.e., individuals with a MoCA
score of<27 were excluded from the healthy control cohort of PPMI, whereas this criterion
was not applied to the other cohorts). Furthermore, the neuropsychological test battery, while
relatively comprehensive in domain coverage, was limited in the number of tests used to exam-
ine each cognitive domain. In addition, some cohorts differed in global cognitive performance,
and this alone may have influenced the differences in cognitive profile as well. Finally, while
the administered cognitive tests preferentially represent specific cognitive domains, there is
overlap in the cognitive domains measured, lowering the strength of the conclusions about
affected cognitive domains.
Despite these limitations, our findings provide insight into the cognitive profile of individu-
als at-risk or in a prodromal state for PD. They lend support to the idea that there is a gradient
of prodromalness that is consistent with the proposed Braak staging, such that individuals
with manifestations presumably resulting from more rostral neurodegeneration, namely the
RBD cohort, have worse cognition than hyposmics or asymptomatic carriers of PD-associated
genes. Longitudinal follow-up of this cohort will yield additional insights across the spectrum
of individuals at risk for PD and other neurodegenerative parkinsonian syndromes.
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